Pelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear

Pelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor RORgammat directs the differentiation system of proinflammatory IL-17+ T helper cells. Cell. 2006;126:11213. 26. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and damaging manage of immune responses. Annu Rev Immunol. 2004;22:5312. 27. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:5314. 28. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;four:330. 29. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription aspect Foxp3. Science. 2003;299:10571. 30. Khattri R, Cox T, Yasayko SA, Ramsdell F. An critical role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003;four:3372. 31. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F. Disruption of a brand new forkhead/winged-helix protein, scurfin, final results within the fatal lymphoproliferative disorder on the scurfy mouse. Nat Genet. 2001;27:683. 32. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature. 2007;445: 7660. 33. Williams LM, Rudensky AY. Upkeep on the Foxp3-dependent developmental program in mature regulatory T cells demands continued expression of Foxp3. Nat Immunol. 2007;eight:2774. 34. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+CD25- naive T cells to CD4 +CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:18756. 35. Selvaraj RK, Geiger TL. A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta. J Immunol. 2007;178:76677. 36. Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA. All-natural and induced CD4+CD25+ cells educate CD4+CD25- cells to create suppressive activity: the part of IL-2, TGF-beta, and IL-10. J Immunol. 2004; 172:52131. 37. Bohmig GA, Krieger PM, Saemann MD, Wenhardt C, Pohanka E, Zlabinger GJ.Pretomanid n-Butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: a possible mechanism for modulating T-cell responses by short-chain fatty acids. Immunology. 1997;92:2343. 38. Gilbert KM, Weigle WO. Th1 cell anergy and blockade in G1a phase on the cell cycle. J Immunol. 1993;151:12454. 39. Siavoshian S, Blottiere HM, Bentouimou N, Cherbut C, Galmiche JP. Butyrate enhances big histocompatibility complex class I, HLA-DR and ICAM-1 antigen expression on differentiated human intestinal epithelial cells.Tralokinumab Eur J Clin Invest.PMID:24406011 1996;26:8030. 40. Butzner JD, Parmar R, Bell CJ, Dalal V. Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. Gut. 1996;38: 5683. 41. Di Sabatino A, Morera R, Ciccocioppo R, Cazzola P, Gotti S, Tinozzi FP, Tinozzi S, Corazza GR. Oral butyrate for mildly to moderately active Crohn’s disease. Aliment Pharmacol Ther. 2005;22:7894. 42. Scheppach W, Sommer H, Kirchner T, Paganelli GM, Bartram P, Christl S, Richter F, Dusel G, Kasper H. Effect of butyrate enemas around the colonic mucosa in distal ulcerative colitis. Gastroenterology. 1992;103:51. 43. Segain JP, Raingeard de la Bletiere D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottiere HM, Galmiche JP. Butyrate inhibits inflammatory responses via NFkappaB inhibition: imp.